Opaxio paclitaxel poliglumex regulatory update

Cell Therapeutics withdrew an MAA for Opaxio paclitaxel poliglumex for first-line treatment of advanced non-small cell lung cancer (NSCLC) in poor performance status (PS2) patients. The company said i...